Table 1.
Clinical Characteristics and Outcomes of the 29 Enrolled Patients.
| Characteristic | No. of Patients (%) |
|---|---|
| AGE, YEARS | |
| Median(range) | 71 (55–87) |
| GENDER | |
| Male | 22 (75.9%) |
| Female | 7 (24.1%) |
| ECOG PERFORMANCE STATUS | |
| 0 | 6 (20.7%) |
| 1 | 14 (48.3%) |
| 2 | 9 (31.0%) |
| SABR INDICATION | |
| Not candidate for surgery | 14 (48.3%) |
| Refuse surgery | 15 (51.7%) |
| STAGE | |
| Ia | 16 (55.2%) |
| Ib | 11 (37.9%) |
| IIa | 2 (6.9%) |
| HISTOLOGY | |
| Adenocarcinoma | 7 (24.1%) |
| Squamous cell | 8 (27.6%) |
| MDT | 14 (48.3%) |
| LOCATION | |
| Central | 3 (10.3%) |
| Peripheral | 26 (89.7%) |
| CUMULATIVE INITIAL EVENTS | |
| LR | 3 (10.3%) |
| RR | 8 (27.6%) |
| DM | 11 (37.9%) |
| DEATH | |
| Due to Lung cancer | 12 (41.4%) |
| Due to other disease | 3 (10.3%) |
| Unknown | 1 (3.4%) |
| Median PFS (95% CI), month | 57.0 (37.6–76.4) |
| Median OS (95% CI), month | 88.0 (35.7–140.3) |
| Median Cost during treatment (range), dollar | 4,838 (4,615–4,923) |
| Median Cost through 5 years (range), dollar | 36,960(9,920–56,824) |
ECOG, Eastern Cooperative Oncology Group; SABR, Stereotactic Ablative Radiotherapy; LR, Local recurrence; RR, Regional recurrence; DM, Distant metastasis; PFS, Progression free survival time; OS, Overall survival time.